OmniAb, Inc. WarrantOABIW
About: OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Employees: 114
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
9% more funds holding
Funds holding: 11 [Q4 2024] → 12 (+1) [Q1 2025]
0.04% less ownership
Funds ownership: 2.43% [Q4 2024] → 2.39% (-0.04%) [Q1 2025]
6% less capital invested
Capital invested by funds: $1.1M [Q4 2024] → $1.03M (-$65.8K) [Q1 2025]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for OABIW.
Financial journalist opinion
We haven’t received any recent news articles for OABIW.